Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul-Aug:36:101788.
doi: 10.1016/j.tmaid.2020.101788. Epub 2020 Jun 12.

Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center

Lucie Pothen  1 , Halil Yildiz  2 , Julien De Greef  2 , Andrea Penaloza  3 , Christophe Beauloye  4 , Leila Belkhir  2 , Jean Cyr Yombi  2
Affiliations
Comment

Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center

Lucie Pothen et al. Travel Med Infect Dis. 2020 Jul-Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Comment on

  • Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
    Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V, Doudier B, Aubry C, Correard F, Giraud-Gatineau A, Roussel Y, Berenger C, Cassir N, Seng P, Zandotti C, Dhiver C, Ravaux I, Tomei C, Eldin C, Tissot-Dupont H, Honoré S, Stein A, Jacquier A, Deharo JC, Chabrière E, Levasseur A, Fenollar F, Rolain JM, Obadia Y, Brouqui P, Drancourt M, La Scola B, Parola P, Raoult D. Million M, et al. Travel Med Infect Dis. 2020 May-Jun;35:101738. doi: 10.1016/j.tmaid.2020.101738. Epub 2020 May 5. Travel Med Infect Dis. 2020. PMID: 32387409 Free PMC article.

References

    1. Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 March 9 doi: 10.1093/cid/ciaa237. Epub ahead of print. - DOI - PMC - PubMed
    1. Chen Z., Hu J., Zhang Z. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020 doi: 10.1101/2020.03.22.20040758. published online March 31, [preprint)] - DOI
    1. Gautret P., Lagier J.-C., Parola P., Hoang V.T., Meddeb L., Mailhe M. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Trav Med Infect Dis. 2020 Apr 11:101663. doi: 10.1016/j.tmaid.2020.101663. Online ahead of print. - DOI - PMC - PubMed
    1. Ferner R.E., Aronson J.K. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432. - DOI - PubMed
    1. McGhie T.K., Harvey P., Su J., Anderson N., Tomlinson G., Touma Z. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol. 2018 Jul-Aug;36(4):545–551. Epub 2018 Apr 13. - PubMed